William Blair Investment Management LLC Reduces Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

William Blair Investment Management LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,241,547 shares of the company’s stock after selling 105,451 shares during the quarter. William Blair Investment Management LLC owned 0.37% of Teva Pharmaceutical Industries worth $93,483,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $66,000. IFP Advisors Inc boosted its stake in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $104,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 2.5 %

Shares of TEVA stock opened at $16.74 on Tuesday. The stock has a market cap of $18.97 billion, a P/E ratio of -11.54, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company’s fifty day simple moving average is $18.19 and its two-hundred day simple moving average is $18.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TEVA shares. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Bank of America lowered their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.